Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H8Br4O10S2.2Na |
| Molecular Weight | 837.997 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[Na+].OC(=O)C1=C(Br)C(Br)=C(Br)C(Br)=C1C(C2=CC=C(O)C(=C2)S([O-])(=O)=O)=C3C=CC(=O)C(=C3)S([O-])(=O)=O
InChI
InChIKey=HXUITPQMHVLBNV-LIYVDSPJSA-L
InChI=1S/C20H10Br4O10S2.2Na/c21-16-14(15(20(27)28)17(22)19(24)18(16)23)13(7-1-3-9(25)11(5-7)35(29,30)31)8-2-4-10(26)12(6-8)36(32,33)34;;/h1-6,25H,(H,27,28)(H,29,30,31)(H,32,33,34);;/q;2*+1/p-2/b13-8+;;
| Molecular Formula | C20H8Br4O10S2 |
| Molecular Weight | 792.018 |
| Charge | -2 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
| Molecular Formula | Na |
| Molecular Weight | 22.98976928 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Sulfobromophthalein (BSP) is a dye with a high affinity for organic anion transporting polypeptides (OATPs) and has been used as a substrate for multidrug resistance associated protein 2 (Mrp2). BSP is transported into hepatocytes by OATPs and, after conjugation to glutathione, is excreted into bile by Mrp2.3 It was found to inhibit the aldo-keto reductase ARK1C20. Sulfobromophthalein (BSP) is used in diagnosis of hepatic disorders.It is also used for the quantitative determination of proteins.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14192521
Curator's Comment: Sulfobromophthalein sodium (BSP, Bromsulphalein) has been used extensively for testing hepatic function since its introduction by Rosenthal and White in 1925
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1697668 |
44.0 nM [Ki] | ||
Target ID: glutathione S-transferase, Oesophagostomum dentatum |
|||
Target ID: CHEMBL2073676 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15618649 |
2.18 µM [Ki] | ||
Target ID: 116852.0 Gene Symbol: Akr1c20 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16508162 |
1.0 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Diagnostic | Bromosulfoftaleina Sodium Approved UseDiagnostic aid in hepatic function determination |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
0.943 mg × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19226651/ |
20 mg/kg single, intravenous dose: 20 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
SULFOBROMOPHTHALEIN plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1551.5 μg × min/mL |
20 mg/kg single, intravenous dose: 20 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
SULFOBROMOPHTHALEIN plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3.07 min |
20 mg/kg single, intravenous dose: 20 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
SULFOBROMOPHTHALEIN plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
5 mg/kg single, intravenous Recommended Dose: 5 mg/kg Route: intravenous Route: single Dose: 5 mg/kg Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
Disc. AE: Diaphoresis, Hypotension... AEs leading to discontinuation/dose reduction: Diaphoresis Sources: Hypotension Consciousness loss |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Consciousness loss | Disc. AE | 5 mg/kg single, intravenous Recommended Dose: 5 mg/kg Route: intravenous Route: single Dose: 5 mg/kg Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
| Diaphoresis | Disc. AE | 5 mg/kg single, intravenous Recommended Dose: 5 mg/kg Route: intravenous Route: single Dose: 5 mg/kg Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
| Hypotension | Disc. AE | 5 mg/kg single, intravenous Recommended Dose: 5 mg/kg Route: intravenous Route: single Dose: 5 mg/kg Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| no [Inhibition 50 uM] | ||||
| yes [IC50 0.05 uM] | ||||
| yes [IC50 7.3 uM] | ||||
| yes [Inhibition 0.52 uM] | ||||
| yes [Inhibition 5 uM] | ||||
| yes [Inhibition 80 uM] | ||||
| yes [Ki 144 uM] | ||||
| yes | ||||
| yes |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| yes [Km 20 uM] | ||||
| yes | ||||
| yes |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Involvement of Mrp2 (Abcc2) in biliary excretion of moxifloxacin and its metabolites in the isolated perfused rat liver. | 2008-01 |
|
| Biliary excretion of flavopiridol and its glucuronides in the isolated perfused rat liver: role of multidrug resistance protein 2 (Mrp2). | 2003-10-17 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15618649
Rats: 350mg/day, i.v.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6019914
In competitive binding studies in vitro between
Sulfobromophthalein (BSP) and a series of organic anions
(sodium fluorescein, indocyanine green, bilirubin,
sodium taurocholate, flavaspidic acid
glucaminate, and iodipamide methylglucamine),
the incubation mixture contained 500 ug of BSP and equimolar amounts of the
aforementional organic anions. On the average,
160 +/- 2 ug BSP was bound per mg of membrane
protein and 1.4 +/-0.1 ug BSP bound
per unit of Co++-CMPase activity in 15
membrane isolates. BSP binding
was maximal at 500 ug BSP/ml in the
incubation mix with proportionately less binding
observed at lower concentrations. BSP
concentrations above 500 ug/ml reduced BSP
binding and produced dissolution of cell membranes.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:22:52 GMT 2025
by
admin
on
Mon Mar 31 21:22:52 GMT 2025
|
| Record UNII |
62E5JU30OV
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C461
Created by
admin on Mon Mar 31 21:22:52 GMT 2025 , Edited by admin on Mon Mar 31 21:22:52 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
62E5JU30OV
Created by
admin on Mon Mar 31 21:22:52 GMT 2025 , Edited by admin on Mon Mar 31 21:22:52 GMT 2025
|
PRIMARY | |||
|
1260372-63-1
Created by
admin on Mon Mar 31 21:22:52 GMT 2025 , Edited by admin on Mon Mar 31 21:22:52 GMT 2025
|
ALTERNATIVE | |||
|
63827
Created by
admin on Mon Mar 31 21:22:52 GMT 2025 , Edited by admin on Mon Mar 31 21:22:52 GMT 2025
|
PRIMARY | |||
|
C87725
Created by
admin on Mon Mar 31 21:22:52 GMT 2025 , Edited by admin on Mon Mar 31 21:22:52 GMT 2025
|
PRIMARY | |||
|
200-761-0
Created by
admin on Mon Mar 31 21:22:52 GMT 2025 , Edited by admin on Mon Mar 31 21:22:52 GMT 2025
|
PRIMARY | |||
|
71-67-0
Created by
admin on Mon Mar 31 21:22:52 GMT 2025 , Edited by admin on Mon Mar 31 21:22:52 GMT 2025
|
PRIMARY | |||
|
Sulphobromophthalein
Created by
admin on Mon Mar 31 21:22:52 GMT 2025 , Edited by admin on Mon Mar 31 21:22:52 GMT 2025
|
PRIMARY | |||
|
300000039633
Created by
admin on Mon Mar 31 21:22:52 GMT 2025 , Edited by admin on Mon Mar 31 21:22:52 GMT 2025
|
PRIMARY | |||
|
CHEMBL574431
Created by
admin on Mon Mar 31 21:22:52 GMT 2025 , Edited by admin on Mon Mar 31 21:22:52 GMT 2025
|
PRIMARY | |||
|
DTXSID9023621
Created by
admin on Mon Mar 31 21:22:52 GMT 2025 , Edited by admin on Mon Mar 31 21:22:52 GMT 2025
|
PRIMARY | |||
|
2183
Created by
admin on Mon Mar 31 21:22:52 GMT 2025 , Edited by admin on Mon Mar 31 21:22:52 GMT 2025
|
PRIMARY | |||
|
SUB15430MIG
Created by
admin on Mon Mar 31 21:22:52 GMT 2025 , Edited by admin on Mon Mar 31 21:22:52 GMT 2025
|
PRIMARY | |||
|
203200
Created by
admin on Mon Mar 31 21:22:52 GMT 2025 , Edited by admin on Mon Mar 31 21:22:52 GMT 2025
|
PRIMARY | RxNorm | ||
|
m10354
Created by
admin on Mon Mar 31 21:22:52 GMT 2025 , Edited by admin on Mon Mar 31 21:22:52 GMT 2025
|
PRIMARY | Merck Index | ||
|
44134957
Created by
admin on Mon Mar 31 21:22:52 GMT 2025 , Edited by admin on Mon Mar 31 21:22:52 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TRANSPORTER -> INHIBITOR | |||
|
|
PARENT -> SALT/SOLVATE |
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|